Kornimate/medical-research-clean huggingface dataset:
transitions clinic network: post incarceration addiction treatment, healthcare, and social support

Conditions: Opioid Addiction

Summary: tcn paths will recruit an anticipated 400 participants who are prescribed moud who are released from detention facilities. each individual will be randomized to either 1) standard primary care (spc) or 2) a transitions clinic network (tcn) program primary care. participants will be followed for a year and complete surveys at baseline and at month 1, 3, 6, 9, and 12. at each of these points research staff will confirm moud status. urine drug screenings will be completed at baseline, month 1, 6, and 12 if the participant is not incarcerated. when possible, research staff will collect electronic health records.

purpose: the overall objective of this study is to assess whether the transitions clinic network (tcn) program, which provides enhanced primary care and opioid use disorder (oud) treatment for people recently released from incarceration, improves measures in the opioid treatment cascade compared to referral to standard primary care. participants: an anticipated 400 individuals currently receiving medications for oud released from eight local jails (durham, nc; minneapolis, mn; bronx, ny; bridgeport and niantic, ct; and bayamón and ponce, puerto rico) procedures: this is a hybrid type i effectiveness-implementation trial will randomize an anticipated 400 participants to one of two treatment conditions: tcn or standard primary care. people will complete the enrollment process while in jail (recruitment, screening, consent, baseline assessments, and randomization). due to covid-19 restrictions some jails are limiting researcher assess to people and some of our sites may enroll participants once they are released, this is referred to as a community enrollment. post participants will meet with research assistants for a structured interview and urine toxicology screening at 1, 6, and 12 months, and a phone interview at months 3 and 9. 120 people will be selected to participate in intensive longitudinal assessment (ila) to access both the acceptability and appropriateness of the tcn intervention and the multi-level facilitators and barriers of oud treatment engagement in the first 30 days following release from incarceration.

Eligibility criteria:
inclusion criteria: * 18 years or older * english and spanish-speaking, * meeting current dsm-5 criteria for oud exclusion criteria: * acutely psychotic, suicidal or homicidal, * require prescription opioids for acute pain, chronic pain or palliative care without oud, * have a planned relocation that makes it unlikely they would be able to complete the study and follow-up assessments, * have a primary care provider that they already have established care with in the community, * women of child-bearing age will be excluded if they are pregnant
pterygomaxillary disjunction with interpositional y-shape plate in patients with temporomandibular joint derangement

Conditions: Temporomandibular Disorder

Summary: temporomandibular joint internal derangement (tmj id) is the most frequent type of temporomandibular disorder (tmds)which is managed by different therapeutic modalities. it begins with conservative methods like medical treatment, physiotherapy, thermotherapy, and bites appliance therapy. surgical intervention is a controversial issue in cases not responding to conservative methods. a novel minimally invasive surgical technique which is extracapsular trans oral (pterygomaxillary disjunction) has been advocated as a minimally invasive extracapsular technique that preserves tmj integrity.


Eligibility criteria:
inclusion criteria: * patients without relevant disease * patients refractory to conservative treatment \> 6 months. * patients are diagnosed, with unilateral/bilateral anterior disc displacement without reduction, clinically and by mri recently. * no previous tmj surgery. * no previous maxillofacial trauma. exclusion criteria: * patients with systemic joint disease (rheumatoid, osteoarthritis, gouts). * medically compromised patients contraindicating operation. * patients to whom general anesthesia is contraindicated. * patient with neuromuscular disorders. * patients with any gross pathology of the ear. * patient with psychoneurotic disorders.
institutional outcome data from per-oral plication of the esophagus

Conditions: Achalasia

Summary: researchers are reviewing and analyzing surgical and clinical outcomes of subjects who underwent pope for end-stage achalasia, a sigmoid esophagus, or a redundant conduit that has been used to replace the esophagus. this data will help researchers determine the safety and efficacy of a novel minimally invasive treatment compared to invasive surgery.

researchers will be collecting electronic medical data for subjects who have already undergone per-oral plication of the esophagus (pope) procedure. subject characteristics, radiographic documentation, videos, procedural details, and subject reported outcomes would be collected. this data will be used for review and analysis to answer questions aimed in this study. data collected from this study will be entered into a database that will be maintained for future research.

Eligibility criteria:
inclusion criteria: * adults \> 18 years of age * patients who have already undergone per-oral plication of the esophagus (pope) procedure exclusion criteria: * patients \<18 years of age

Keywords: pope
a study of cm310 in subjects with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of cm310 in subjects with moderate-to-severe atopic dermatitis.

the study consists of an screening period, treatment period, and safety follow-up period.

Eligibility criteria:
inclusion criteria: * have the ability to understand the study and voluntarily sign a written informed consent form (icf). * age ≥ 18 and ≤ 75 years old. * with atopic dermatitis. exclusion criteria: * not enough washing-out period for previous therapy. * concurrent disease/status which may potentially affect the efficacy/safety judgement. * major surgeries are planned during the study period.
adp101 for oral immunotherapy in food-allergic children and adults

Conditions: Food Allergy

Summary: the purpose of this study is to assess the efficacy and safety of adp101 in food allergic children and adults.

this is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of adp101 for oral immunotherapy in food allergic children and adults.

Eligibility criteria:
inclusion criteria: * age 4 to 55 (inclusive) * clinical history of allergy to at least 1 of the foods contained in adp101 * experience dose-limiting symptoms at or below the 100-mg dose level to 1 or multiple food sources in adp101 exclusion criteria: * experience dose limiting symptoms at or below the 100 mg challenge dose level to more than 5 food sources contained in adp101 * history of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock within 60 days of screening * history of eoe, other eosinophilic gastrointestinal disease, chronic, recurrent or severe gerd, symptoms of dysphagia * severe asthma * mild or moderate asthma, if uncontrolled or difficult to control * history of mast cell disorder, including mastocytosis, urticaria pigmentosa or angioedema * history of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) at risk of becoming unstable or requiring a change in chronic therapeutic regimen e.g. uncontrolled diabetes * history of cardiovascular disease, including hypertension requiring \> 2 antihypertensive medications * history of interstitial lung disease * history of celiac disease * active autoimmune disease that has required systemic treatment within 3 months * known malignancy that is progressing or has required active treatment within the past 3 years * known history of hiv, known active hepatitis b infection or known active hepatitis c virus infection * prior/concurrent therapies as follows: * beta-blockers, ace inhibitors, arbs or calcium channel blockers * regular steroid medication use * therapeutic antibody treatment currently or within the previous 6 months * any food immunotherapy currently or within the previous 12 weeks * in the build up phase of non-food immunotherapy * residing at the same address as another subject (e.g. siblings) participating in this or any other oit study * develops dose-limiting symptoms to placebo during the screening dbpcfc * any other condition that might preclude safe participation in the study

Keywords: adp101 allergy oral immunotherapy oit allergies food allergies multi-food allergic multi-allergen oral immunotherapy tree nut allergy milk allergy wheat allergy egg allergy fin fish allergy shrimp allergy peanut allergy sesame seed allergy soy allergy shellfish allergy fish allergy seafood allergy dairy allergy desensitization food hypersensitivity immune system disease hypersensitivity, immediate hypersensitivity
telemedicine qualifying transition between tertiary and primary health care in stable coronary artery disease patients

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine whether the telemedicine use in primary health care is effective in the accompaniment of stable coronary artery disease patients who were discharged from the tertiary health care clinics.

this study is a randomized non-inferiority trial for patients with chronic coronary artery disease from a tertiary hospital with outpatient discharge criteria. the purpose is to compare the use of telemedicine in the quality of care transition between tertiary care and primary care patients (intervention group), with patients who remain in the outpatient clinic of a tertiary hospital (control group).

Eligibility criteria:
inclusion criteria: * individuals with diagnosis of coronary artery disease (cad) in canadian cardiovascular society (ccs)'s functional classification of angina class i or ii * patients who did not submit hospitalization for cardiovascular disease in the last year exclusion criteria: * patients who were not followed up in the health service to at least one year * unstable patients requiring adjustments of medications or who are performing some diagnostic evaluation at discharge outpatient

Keywords: coronary artery disease stable telemedicine patient discharge
trial of forodesine in patients with relapsed b-cell chronic lymphocytic leukemia

Conditions: B-cell Chronic Lymphocytic Leukemia

Summary: to determine the dose and duration of treatment for the best overall response with forodesine in relapsed b-cell chronic lymphocytic leukemia

an open label, multi centre, three arm, dose finding phase 1 trial with forodesine as a single drug treatment in patients with relapsed cll to establish dose and duration of treatment resulting in the best achievable response with forodesine as a single drug treatment.

Eligibility criteria:
inclusion criteria: * patients with confirmed binet stage b or c b-cll as defined by the national cancer institute (nci) sponsored working group who have received up to 2 previous lines of treatment, one of which was fludarabine based. the two previous treatments could have included combination therapies. * patients must be ≥18 years of age, have a life expectancy of \>6 months, and an eastern cooperative oncology group (ecog) performance status of 0, 1, or 2. - female patients must not be pregnant (as confirmed by negative pregnancy test for women of childbearing potential) and female and male patients must be willing to use effective contraception for the entire duration of treatment and 2 months thereafter. exclusion criteria: * patients who have received more than 2 previous lines of treatment will be excluded from this study. * additional groups of patients who may not participate in the study include: patients who are pregnant and/or nursing; patients on corticosteroid treatment; patients with active infection (bacterial, viral or fungal) or severe infection (who 4th degree) within the last 3 months; patients with total bilirubin \> 2 × uln; patients with calculated creatinine clearance \<70 ml/min; patients with seropositivity for human immunodeficiency virus, hepatitis b virus, or hepatitis c virus; patients with any coexisting medical or psychological condition that would preclude participation in the required study procedures; patients who have participated in another clinical study \<6 weeks prior to this study; or patients with a known hypersensitivity to the study medication.

Keywords: leukemia, cll
investigating bladder field-cycling imaging

Conditions: Bladder Cancer

Summary: the goal of this pilot study is explore the parameters that can be obtained in bladder tumours by field-cycling imaging (fci) in patients with both muscle-invasive and non-muscle invasive tumours. the main question it aims to answer is if fci can give more diagnostic information than conventional tests. participants will have one fci scan and the results will be correlated with the results of ct urogram or ct scan.

patients with organ-confined muscle invasive bladder cancer are treated either by removal of their bladder at cystectomy or by organ-preserving treatment, generally following neoadjuvant chemotherapy. in some cases, the neoadjuvant chemotherapy can shrink the tumour so that it is clinically undetectable but there may still be tumour cells present microscopically. this presents a difficulty during planning of radiotherapy treatments, which could then miss the tumour and lead to tumour recurrence. field-cycling imaging (fci) is an emerging imaging technology pioneered at the university of aberdeen. fci can image human tissues non-invasively over a wide range of magnetic field strengths, directly informing on multi-scale tissue structure from nanometres to micrometres. fci has already shown significant potential for enhanced diagnosis in a range of diseases, and recent results show several potential biomarkers of cancer in breast, colon, and brain. fci has not been used in bladder cancer before. in this proof-of-concept study, we will recruit patients with both muscle-invasive and non-muscle invasive tumours to explore the parameters that can be obtained in bladder tumours by fci. results of the fci scans will be correlated with the results of ct urogram or ct scan.

Eligibility criteria:
inclusion criteria: * patients attending for flexible cystoscopy found to have a tumour of at least 3 cm in diameter (muscle-invasive or non-muscle invasive) * participants must be aged 18 and above * participants who meet the safety criteria for undergoing an mri scan * participants who are able to fit inside the scanner * participants must be able to give fully informed consent * participants must be mobile enough to be positioned onto the fci scanner couch exclusion criteria: * patients with total hip replacement * mri-incompatible conditions, as detected in the mri safety screening sheet * participants under 18 years old * participants who are unable to communicate in english * participants who are unable to give fully informed consent * women who are pregnant * restrictions to mobility that would prevent the correct positioning in the scanner * participants who suffer from claustrophobia

Keywords: bladder cancer bladder tumours field-cycling imaging
subclassification of the syndrome of inappropriate adh secretion

Conditions: Hyponatremia

Summary: the aim of this study is to evaluate the different types of osmotic dysregulation in patients with syndrome of inappropriate adh (siadh) and, hence, to analyze the pathophysiology of siadh. these types will be characterized by measurement of avp and copeptin while performing an osmotic stimulation with infusion of hypertonic saline.


Eligibility criteria:
inclusion criteria: * age \> 18 years, * hyponatremia \< 132 mmol/l * siadh exclusion criteria: * age \< 18 years * cerebral metastases * serum sodium \> 132mmol/l

Keywords: hyponatremia siadh copeptin
the influence of cerebral blood flow and petco2 on neuromuscular function during passive heat stress

Conditions: Healthy Males; Neuromuscular Function

Summary: increased core temperature (hyperthermia) has been associated with impaired neuromuscular performance; however, the mechanisms associated with these performance decrements and their potential synergies remain unclear. while the majority of research suggests that the observed fatigue is related to the central nervous system, the influence of changes in cerebral blood flow (cbf) and associated changes in cerebral alkalosis (estimated by end-tidal partial pressure of carbon dioxide; petco2) remains unexamined. in response to hyperthermia, humans hyperventilate as means of heat dissipation, resulting in a hypocapnia (reduced petco2) mediated decrease in cbf and consequently, cerebral alkalosis (increased cerebral ph). previous research suggests that hyperventilation induces changes in neural excitability and synaptic transmission; however, it remains unclear if these changes are related to hypocapnia mediated decrease in cbf or decreased petco2 or both. the purpose of the proposed research program is to examine the influence of changes in cbf and cerebral alkalosis on neuromuscular function during passive heat stress. the research project will consist of 3 separate experimental trials: (a) poikilocapnic hyperthermia (increased core temperature; decrease cbf; decrease petco2), (b) isocapnic hyperthermia (increased core temperature; no change cbf; no change petco2) and (c) isocapnic hyperthermia + indomethacin (increased core temperature; decrease cbf; no change petco2). during each manipulation, neuromuscular function will be evaluated and compared to baseline (normothermic) conditions using a repeated measures design. it is hypothesized that changes in petco2 and therefore, changes in cerebral alkalosis will contribute to neuromuscular fatigue independent of changes in cbf or increases in core temperature.


Eligibility criteria:
inclusion criteria: * 18 to 45 yrs old; healthy males exclusion criteria: * diagnosed medical condition; nsaid allergy; smoker; high altitude exposure; implants
women with chest pain and no significant coronary artery stenosis; a study on microvascular resistance

Conditions: Angina Pectoris

Summary: female patients presenting with persistent chest pain despite no obstructive coronary artery disease have impaired prognosis. stress tests are often positive or inconclusive. as much as 20% of women with chest pain and minimal angiographic cad have evidence of myocardial ischemia, suggesting impaired coronary microcirculation. the index of microvascular resistance (imr) is a method for indirectly investigating microvascular function in the cardiac catheterization laboratory. 66 female patients, age 30-70 years, with chest pain and "normal" or near normal coronary angiograms will be included. after coronary physiologic evaluation, patients will be randomized in a double blind study to rosuvastatin 20 mg/day or matching placebo tablets for altogether 6 months. the investigators hypothesize that: 1. a substantial number of women with chest pain and normal or minimal pathology on angiograms have microvascular dysfunction defined by a raised imr. 2. statins, based on its pleiotropic action will improve endothelial function and thereby imr.


Eligibility criteria:
inclusion criteria: 1. female gender 2. age 30 - 70 years 3. chest pain suggestive of symptomatic coronary artery disease 4. a coronary angiogram with no or minimal coronary artery disease 5. fractional flow reserve value over 0,80 exclusion criteria: 1. male gender 2. age under 30 years or over 70 3. coronary artery stenosis ≥ 33 % in any epicardial vessel 4. fractional flow reserve value ≤ 0,80 5. pregnant or nursing women 6. women of childbearing potential not using contraception 7. short life expectancy 8. uncontrolled endocrinological disease 9. arterial hypertension 10. structural heart disease 11. significant mental disorder, including dementia 12. inability to comply with the protocol -
weight-adjusted dosing of 3-ohb in patients with chronic heart failure

Conditions: Heart Failure; Ketosis

Summary: we aim to investigate the hemodynamic effects of weight-adjusted dosing of ketone monoester en patients with chronic heart failure.


Eligibility criteria:
inclusion criteria: chronic hf: nyha class ii-iii, left ventricular ejection fraction (lvef) \<40% exclusion criteria: diabetes or hba1c \>48 mmol/mol, significant cardiac valve disease, severe stable angina pectoris, severe comorbidity as judged by the investigator, inability to give informed consent

Keywords: hemodynamics
the effects of observer presence and type on patients' perception of exercise in patients with soft tissue sarcoma

Conditions: Soft Tissue Sarcoma

Summary: the primary aim of the study is to investigate the effects of supervised exercise, telerehabilitation and home-based exercise on patient perception in patients with soft tissue sarcoma. the secondary aim of the study is to identify the barriers to starting exercise in these patients.

an exploratory-descriptive qualitative study will be conducted. there will be three groups in the study with each of them will consist of ten participants. within the scope of the study, each group will perform a similar exercise program, 2 sessions a week, for 6 weeks, in one of the 3 groups below; group 1: exercising under the supervision of a face-to-face physiotherapist, group 2: exercise under the observation of the physiotherapist via video-conference (telerehabilitation), group 3: exercising in the absence of the observer (home based exercise program). the exercises to be applied to the groups will include breathing exercises, passive range of motion exercises and strengthening exercises. semi-structured focus group interviews will be held with the participants twice, before and after the 6-week exercise program. in the semi-structured focus group interviews, the same questions will be asked to all participants and the verbal answers to these questions will be recorded with voice recorders. compared to taking notes by hand; it will be preferable to record the conversation with a voice recorder because it has advantages such as recording all the interviews and allowing the interviewer to focus on the interview. in the pre-exercise interview, questions will be asked to determine the patient's views about exercises and the barriers to starting the exercise. in the interview held at the end of the exercise program, questions will be asked to learn the views/perceptions of the patients about the results of the exercise program. thematic analysis method will be used in the evaluation of the data.

Eligibility criteria:
inclusion criteria: * individuals aged between 18 and 65, * individuals without communication problems, * individuals who have been diagnosed with soft tissue sarcoma * ecog score ≤2 exclusion criteria: * uncontrollable arrhythmia and/or hypertension * presence of advanced sensory deficit * visual and hearing problems * not having sufficient communication skills (mini mental test score below 24 points) * ecog score\>2

Keywords: soft tissue sarcoma exercise telerehabilitation